Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Whys, Whens, and Hows of Futility Monitoring.

Statistics in medicine·2025
Same author

Statistical Methods for Clinical Study Site Selection.

Therapeutic innovation & regulatory science·2020
Same author

Human red and green cone opsins are <i>O</i>-glycosylated at an N-terminal Ser/Thr-rich domain conserved in vertebrates.

The Journal of biological chemistry·2019
Same author

Improving Plant Genome Editing with High-Fidelity xCas9 and Non-canonical PAM-Targeting Cas9-NG.

Molecular plant·2019
Same author

Likelihood-Ratio-Test Methods for Drug Safety Signal Detection from Multiple Clinical Datasets.

Computational and mathematical methods in medicine·2019
Same author

Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis.

Science advances·2019

Related Experiment Video

Updated: May 15, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.

Lan Huang1, Jyoti Zalkikar, Ram C Tiwari

  • 1Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, USA. lan.huang@fda.hhs.gov

Journal of Biopharmaceutical Statistics
|January 22, 2013
PubMed
Summary

This study enhances drug safety analysis by extending the likelihood ratio test (LRT) method to detect adverse event (AE) signals for drug classes, not just single drugs. The new approach controls statistical errors, improving postmarket drug safety monitoring.

More Related Videos

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity
12:02

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity

Published on: June 2, 2014

Related Experiment Videos

Last Updated: May 15, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity
12:02

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity

Published on: June 2, 2014

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Biostatistics
  • Regulatory Science

Background:

  • The Food and Drug Administration (FDA) uses the Adverse Event Reporting System (AERS) database for postmarket drug safety monitoring.
  • Existing statistical methods for analyzing AERS data primarily focus on single drug-adverse event (AE) combinations and struggle with controlling statistical errors.
  • There is a need for methods that can identify safety signals involving drug classes or groups of AEs while maintaining statistical rigor.

Purpose of the Study:

  • To extend the likelihood ratio test (LRT)-based method for detecting safety signals involving drug classes or groups of AEs.
  • To introduce a simplified Bayesian method as an alternative for signal detection.
  • To evaluate the performance of these extended methods using real-world AERS data for specific drug classes.

Main Methods:

  • Review of the existing LRT-based method for controlling family-wise type I error and false discovery rates.
  • Extension of the LRT method using a weight matrix to accommodate drug classes or AE groups.
  • Development and comparison of a simplified Bayesian method alongside the extended LRT approach.

Main Results:

  • The extended LRT method successfully identifies safety signals for drug classes, such as gadolinium-based contrast agents and statins, from AERS data.
  • The proposed statistical methods demonstrate improved control over statistical errors compared to traditional approaches.
  • The identified signals were validated through comparisons with other databases, existing medical literature, and simulation studies.

Conclusions:

  • The enhanced LRT and Bayesian methods provide robust tools for detecting complex drug safety signals in large postmarket databases.
  • These advanced statistical approaches improve the accuracy and reliability of drug safety signal detection, particularly for drug classes.
  • The findings support more effective postmarket drug safety surveillance and regulatory decision-making.